Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM03 in moderate-to-severe active rheumatoid arthritis
NCT04192617Phase 2Completed
- Sponsor
- SinoMab BioScience Limited
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of suciraslimab in rheumatoid arthritis (RA) (3 arms), sponsored by SinoMab BioScience Limited. Primary endpoint: American College of Rheumatology 20 Response at 24 weeks. Started Dec 2014; status: completed.
02
Drugs
suciraslimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04192617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192617.